News

Grown Rogue International Prepares for Q2 2025 Financial Insights

Grown Rogue International Prepares for Q2 2025 Financial Insights

Grown Rogue International Announces Upcoming Q2 2025 Financial Results

Grown Rogue International Inc. (CSE: GRIN, OTC: GRUSF), a leading name in the cannabis industry, is gearing up to share its financial results for the second quarter. The report will detail the company's performance ending June 30, 2025, and is expected to be released after market close on August 12, 2025.

Understanding the Financial Reporting Process

This financial report serves as a crucial marker for Grown Rogue as it reflects the company's growth trajectory and operational efficiency. Investors and stakeholders will gain insights into the company's revenue streams and profitability ratios, which are vital for making informed investment decisions. Following the release, Grown Rogue will host a conference call to discuss these results and provide updates on corporate strategies.

Details of the Conference Call

The management team, including CEO Obie Strickler, will conduct the call on August 12, 2025, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). This provides a platform for investors to directly engage with the company’s leadership, allowing them to ask questions and gain a deeper understanding of the company’s operations and future plans.

Conference Call Registration and Access Information

Participating in the conference call is quite straightforward. Investors and interested parties can register for the call via the company’s website. Dial-in numbers are provided for North American callers, ensuring accessibility. The toll-free numbers for North America and Canada are 1-800-836-8184, which allows for easy access to the discussion.

Replay and Further Engagement

After the call, a replay will be available until August 19, 2025. This will allow those unable to attend the live session to listen at their convenience. Additionally, the recorded webcast will be archived on Grown Rogue's Investor Relations website for around 90 days, providing another avenue for stakeholders to stay informed.

About Grown Rogue International Inc.

Founded and operating out of Oregon, Grown Rogue International Inc. is strategically positioned within the cannabis market. The company's focus on high-quality indoor flower products has set it apart from competitors. Their commitment to combining craft cultivation with robust operational efficiency is at the core of their strategy, aimed at enhancing product quality and consistency. This dedication has solidified their reputation among retailers, budtenders, and consumers alike.

Expansion and Market Strategies

Grown Rogue is not just confined to its roots in Oregon; the company is expanding into key markets like Michigan and New Jersey and is actively pursuing opportunities in Illinois. This expansion showcases their ambition to capture a larger share of the cannabis market while maintaining their standards of quality.

Contact Information for Inquiries

Should stakeholders require further information or assistance, they can reach out via email at invest@grownrogue.com. This commitment to open communication highlights Grown Rogue's dedication to transparency and investor relations.

Frequently Asked Questions

What are Grown Rogue's main products?

Grown Rogue specializes in high-quality indoor cannabis flower, known for its exceptional consistency and cultivation care.

When will the financial results be available?

The financial results for Q2 2025 will be reported on August 12, 2025, after market close.

How can I participate in the conference call?

Interested parties can join the call by registering on the company’s website and dialing in using the provided toll-free numbers.

What if I miss the live call?

A replay of the conference call will be available until August 19, 2025.

Who can I contact for more information?

For questions or additional information, you can email invest@grownrogue.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 501

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 595

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 18

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Initiated for Voyager Therapeutics Investors

Updated Category News Views 115

Investigation Overview for Voyager Therapeutics Investors Pomerantz LLP is currently exploring possible claims on behalf of investors in Voyager Therapeutics, Inc. (NASDAQ: VYGR). This exploration arises from concerns surrounding the company’s recent announcements and operational strategies. Details of the Investigation The inquiry focuses on whether Voyager and some of...

Continue Reading
Subway's Creative Middle Seat Reward for Travelers

Updated Category News Views 132

Subway Announces Exciting Promotion for Air Travelers On January 27, a significant change is happening for travelers, especially for those who dread sitting in the middle seat of a plane. With a popular airline ending its open seating policy, millions are gearing up for assigned seating. This means that many passengers might find themselves in the middle seat, which is...

Continue Reading
Expanse Studios Unveils Innovative Games at Major Summit

Updated Category News Views 86

Expanse Studios Shines at Industry Summit Expanse Studios, a cutting-edge gaming developer and a subsidiary of Golden Matrix Group Inc. (NASDAQ: GMGI), has made a significant impression at the recent SBC Summit Lisbon. This event attracted around 25,000 attendees, featuring a mix of gaming innovators and industry experts, all eager to explore what's next in the gaming...

Continue Reading
Unlocking Digital Preservation Skills Through New Academy

Updated Category News Views 150

Introducing the Preservica Academy for Digital Preservation Preservica Inc. has unveiled its exciting new initiative, Preservica Academy, dedicated to enhancing the skills of professionals and beginners in the realm of digital preservation. This innovative program focuses on Active Digital Preservation™, aiming to ensure the long-term accessibility and integrity of...

Continue Reading
Seritage Growth Properties Investors Alert: Class Action Lawsuit Update

Updated Category News Views 107

Notification of Class Action Lawsuit for Seritage Growth Properties Levi & Korsinsky, LLP is reaching out to inform investors of Seritage Growth Properties (NYSE: SRG) regarding an ongoing class action securities lawsuit. This case marks an important development for those affected by alleged securities fraud. Overview of the Class Action Lawsuit This lawsuit is centered...

Continue Reading